Research Reports | Market Assessment
November 2016

Biosimilars | Emerging Biosimilars | Oncology | Zarxio Wave 3 | US | 2016

Biosimilars | Emerging Biosimilars | Oncology: Zarxio Launch Tracking (US) Wave 3 is the third and final installment in a series of syndicated reports designed to track physician perception and uptake of Sandoz’s Zarxio (filgrastim-sndz), a biosimilar of Amgen’s Neupogen and the first biosimilar to launch in the United States. Medical oncologists and hematology-oncologists in the United States were surveyed to assess their awareness and perception of Zarxio, uptake of the biosimilar over time, Zarxio’s effect on other G-CSFs, and promotional activity related to Zarxio and its competitors. Formulary coverage and restrictions associated with Zarxio and other G-CSFs were also evaluated.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports